Current market catalysts

William Blair Upgrades FactSet Research Systems to Outperform

Blue Owl Technology's $800M Financing Run Puts Dividend Coverage In Focus

The Print Blue Owl Technology Finance Corp. (NYSE:OTF) closed a $150 million private placement of 7.60% senior unsecured notes due September 3, 2032, on September 4. The deal was the company’s third financing since

8-K/A filing — RIVERVIEW BANCORP INC (RVSB)

Filed: 2026-09-08 AccNo: 0000939057-26-000233 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

UBS Maintains Buy on Peloton Interactive, Lowers Price Target to $10

SpaceX Bull Case 'Rests Almost Entirely' on Starship Reuse. Analyst Says Buy Anyway

Pivotal Research rates SpaceX a Buy with a $220 target, hinging on Starship's reusability.

If You Invested $100 In CrowdStrike Holdings Stock 5 Years Ago, You Would Have This Much Today

CrowdStrike Holdings (NASDAQ:CRWD) has outperformed the market over the past 5 years by 15.38% on an annualized basis producing an average annual return of 26.8%. Currently, CrowdStrike Holdings has a market

RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

UBS Maintains Buy on Marathon Petroleum, Raises Price Target to $450

How To Trade SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, And TSLA

Good Morning Traders! Today’s economic calendar kicks off the shortened trading week with limited scheduled data. The primary economic release comes at 11:00AM ET with the New York Fed’s 1-Year Inflation

Jeff Bezos, Cathie Wood Argue That AI Will Create a Labor Shortage, Not Job Losses

Jeff Bezos and Cathie Wood say AI could create a labor shortage instead of mass job losses. Here's why they share that view.

RBC Capital Reiterates Outperform on HCA Healthcare, Maintains $435 Price Target

UBS Maintains Buy on Phillips 66, Raises Price Target to $300

'Canada In Talks to Sell Nuclear-Power Technology, LNG to Poland' - Bloomberg

Verisk Analytics shares are trading lower after Barclays lowered its price target on the stock from $275 to $225.

Dyne Therapeutics shares are trading lower. The company announced it will present additional one-year Phase 1/2 ACHIEVE trial data for zeleciment basivarsen in DM1 at the 31st WMS Congress and the 2026 AANEM Annual Meeting.

UBS Maintains Buy on HF Sinclair, Raises Price Target to $126

RBC Capital Reiterates Outperform on Colgate-Palmolive, Maintains $104 Price Target

UBS Maintains Buy on Valero Energy, Raises Price Target to $450

Beam Therapeutics shares are trading lower. The company announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency.

Royalty Pharma shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint. The company had signed a $500 million funding agreement with Novartis partner Ionis that would have contributed pelacarsen royalties.

X-Energy shares are trading higher. Guggenheim reiterated the stock with a Buy rating and maintained a $57 price target.

If You Invested $100 In Bloom Energy Stock 5 Years Ago, You Would Have This Much Today

Bloom Energy (NYSE:BE) has outperformed the market over the past 5 years by 57.06% on an annualized basis producing an average annual return of 68.47%. Currently, Bloom Energy has a market capitalization of $80.82

Swvl Holdings shares are trading higher after the company announced that HSBC Bank has increased the limit on the company’s working capital facility by 110% to $1.4 million.

Enphase Energy shares are trading higher after the company announced that power modules for its IQ Solid-State Transformer are now being built in the U.S. to assemble and validate full-scale IQ SST racks.

Steve Eisman Owns AIG as Cantor Calls Stock ‘Really, Really Cheap’

Steve Eisman says he owns AIG as Cantor backs the insurer as a cheap “self-help story” with about 17% upside to its target.

Apple's Wednesday Event: Pricier iPhone 18 Pros and a $2,099 Foldable Expected

Bank of America maintains Buy on Apple with a $380 target before Wednesday's event, expecting a $2,099 foldable and $150-$200 Pro price hikes.

UBS Maintains Neutral on General Dynamics, Raises Price Target to $408

UBS Maintains Buy on Northrop Grumman, Raises Price Target to $704

UBS Upgrades EchoStar to Buy, Raises Price Target to $150

Inhibrx Biosciences shares are trading lower. The company announced primary endpoint results from the Phase 2 HexAgon study of INBRX-106, an OX40 agonist, combined with pembrolizumab versus pembrolizumab alone in PD-L1 positive head and neck squamous cell carcinoma.